Forbes February 5, 2024
According to a federal government Medicare Payment Advisory Commission report published last month, more than 40% of Medicare beneficiaries still have no access through their insurance to Humira-referenced biosimilars, despite several products having discounts of over 80% compared to the original Humira. When biosimilars are covered they’re usually on the same patient cost-sharing tier as Humira, which doesn’t favor their uptake. This is more than seven years after the first Humira-referenced biosimilar was approved by the Food and Drug Administration, and one year after biosimilars were permitted to launch in the U.S.
AbbVie now says it can protect Humira’s market share until 2025 or 2026, according to Endpoints News. Given that the autoimmune disease product has lost merely 2% of...
Today's Sponsors
Today's Sponsor